Oxidative Stress, Nrf2, and Epigenetic Modification Contribute to Anticancer Drug Resistance

Nuclear factor E2-related factor 2 (Nrf2), a transcription factor, controls the expression of genes encoding cytoprotective proteins, including antioxidant enzymes that combat oxidative and electrophilic stress to maintain redox homeostasis. However, recent studies demonstrated that, in cancer, aber...

Full description

Saved in:
Bibliographic Details
Published inToxicological research (Seoul) Vol. 33; no. 1; pp. 1 - 5
Main Authors Kang, Kyoung Ah, Hyun, Jin Won
Format Journal Article
LanguageEnglish
Published Singapore Springer Singapore 01.01.2017
Korean Society of Toxicology
한국독성학회
Subjects
Biomedicine
Invited Review
Pharmacology/Toxicology
예방의학
Nrf2 transcription factor
Oxidative stress
Anticancer drug resistance
Epigenetic modification
Online AccessGet full text
ISSN1976-8257
2234-2753
DOI10.5487/TR.2017.33.1.001

Cover

More Information
Summary:Nuclear factor E2-related factor 2 (Nrf2), a transcription factor, controls the expression of genes encoding cytoprotective proteins, including antioxidant enzymes that combat oxidative and electrophilic stress to maintain redox homeostasis. However, recent studies demonstrated that, in cancer, aberrant activation of Nrf2 by epigenetic alterations promotes high expression of cytoprotective proteins, which can decrease the efficacy of anticancer drugs used for chemotherapy. In this review, we summarize recent findings regarding the relationship between oxidative stress, Nrf2, epigenetic modification, and anticancer drug resistance, which should aid in development of new strategies to improve chemotherapeutic efficacy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
G704-000933.2017.33.1.001
ISSN:1976-8257
2234-2753
DOI:10.5487/TR.2017.33.1.001